Ofranergene Obadenovec

Summary

Ofranergene Obadenovec (CHEMBL3707381) is a phase-3 clinical-stage gene; indicated across 4 conditions including ovarian cancer and glioblastoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 4 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707381
Name	Ofranergene Obadenovec
Type	Gene
Max phase	3

Also known as: Ofranergen obadenovec, Ofranergene obadenovec, VB-111, OFRANERGENE OBADENOVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ovarian cancer	3	MONDO:0008170	MONDO:0008170
glioblastoma	1	MONDO:0018177	EFO:0000519
neoplasm	1	MONDO:0005070	MONDO:0004992

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02511405	PHASE3	COMPLETED	A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
NCT03398655	PHASE3	COMPLETED	A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)
NCT01229865	PHASE2	COMPLETED	Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
NCT01260506	PHASE1/PHASE2	COMPLETED	Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
NCT00559117	PHASE1	UNKNOWN	A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).